152 related articles for article (PubMed ID: 35580293)
21. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
22. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance.
Bagchi S; Yuan R; Engleman EG
Annu Rev Pathol; 2021 Jan; 16():223-249. PubMed ID: 33197221
[TBL] [Abstract][Full Text] [Related]
23. The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy.
Mpakali A; Stratikos E
Cancers (Basel); 2021 Jan; 13(1):. PubMed ID: 33406696
[TBL] [Abstract][Full Text] [Related]
24. Prospective Clinical Investigation of the Efficacy of Combination Radiation Therapy With Immune Checkpoint Inhibition.
Akama-Garren EH; Morris ZS; Sikora AG; Weichselbaum R; Schoenfeld JD
Int J Radiat Oncol Biol Phys; 2021 Dec; 111(5):1165-1175. PubMed ID: 34411638
[TBL] [Abstract][Full Text] [Related]
25. Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer.
Kobayashi Y; Lim SO; Yamaguchi H
Semin Cancer Biol; 2020 Oct; 65():51-64. PubMed ID: 31874279
[TBL] [Abstract][Full Text] [Related]
26. The effect of adding immune checkpoint inhibitors on the risk of pneumonitis for solid tumours: a meta-analysis of phase III randomised controlled trials.
Fujiwara Y; Horita N; Namkoong H; Galsky MD
Eur J Cancer; 2021 Jun; 150():168-178. PubMed ID: 33906099
[TBL] [Abstract][Full Text] [Related]
27. CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy.
Lai AY; Sorrentino JA; Dragnev KH; Weiss JM; Owonikoko TK; Rytlewski JA; Hood J; Yang Z; Malik RK; Strum JC; Roberts PJ
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33004541
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review.
Ulas EB; Dickhoff C; Schneiders FL; Senan S; Bahce I
ESMO Open; 2021 Oct; 6(5):100244. PubMed ID: 34479033
[TBL] [Abstract][Full Text] [Related]
29. Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma.
Hotta K; Fujimoto N
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32098830
[TBL] [Abstract][Full Text] [Related]
30. Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver.
Hewitt DB; Rahnemai-Azar AA; Pawlik TM
Expert Opin Investig Drugs; 2021 Aug; 30(8):827-835. PubMed ID: 34102935
[No Abstract] [Full Text] [Related]
31. Neutrophils in the era of immune checkpoint blockade.
Faget J; Peters S; Quantin X; Meylan E; Bonnefoy N
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34301813
[TBL] [Abstract][Full Text] [Related]
32. The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors.
Bissonnette RP; Cesario RM; Goodenow B; Shojaei F; Gillings M
BMC Cancer; 2021 Aug; 21(1):969. PubMed ID: 34461854
[TBL] [Abstract][Full Text] [Related]
33. Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite.
Renga G; Nunzi E; Pariano M; Puccetti M; Bellet MM; Pieraccini G; D'Onofrio F; Santarelli I; Stincardini C; Aversa F; Riuzzi F; Antognelli C; Gargaro M; Bereshchenko O; Ricci M; Giovagnoli S; Romani L; Costantini C
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35236743
[TBL] [Abstract][Full Text] [Related]
34. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.
Li X; Wang Y; Li X; Feng G; Hu S; Bai Y
Front Immunol; 2021; 12():638763. PubMed ID: 34305884
[TBL] [Abstract][Full Text] [Related]
35. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
36. Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition.
Yuan J; Khilnani A; Brody J; Andtbacka RHI; Hu-Lieskovan S; Luke JJ; Diab A; Marabelle A; Snyder A; Cao ZA; Hodi FS
Eur J Cancer; 2021 Nov; 157():493-510. PubMed ID: 34561127
[TBL] [Abstract][Full Text] [Related]
37. Recent advances of immunotherapy for biliary tract cancer.
Rizzo A; Ricci AD; Brandi G
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):527-536. PubMed ID: 33215952
[No Abstract] [Full Text] [Related]
38. Managing side effects of immune checkpoint inhibitors in breast cancer.
Criscitiello C; Corti C; Pravettoni G; Curigliano G
Crit Rev Oncol Hematol; 2021 Jun; 162():103354. PubMed ID: 34029683
[TBL] [Abstract][Full Text] [Related]
39. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Bai J; Liang P; Li Q; Feng R; Liu J
Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
[TBL] [Abstract][Full Text] [Related]
40. Anti-PD-1 Therapy-Associated Type 1 Diabetes in a Pediatric Patient With Relapsed Classical Hodgkin Lymphoma.
Samoa RA; Lee HS; Kil SH; Roep BO
Diabetes Care; 2020 Sep; 43(9):2293-2295. PubMed ID: 32616607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]